Brief: Bioarctic AB Says Leqembi Approved For Treatment Of Alzheimer's Disease In Hong Kong
11/07/2024 24:32
July 10 (Reuters) - BioArctic AB BIOAb.ST :
* BIOARCTIC AB- LEQEMBI APPROVED FOR TREATMENT OF
ALZHEIMER'S
DISEASE IN HONG KONG
Source text for Eikon: ID:nWkrbRRydk
Further company coverage: BIOAb.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln